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AZD0530, an orally available Src inhibitor, demonstrated potent antimigratory and anti-
invasive effects in vitro, and inhibited metastasis in a murine model of bladder cancer.
Antiproliferative activity of AZD0530 in vitro varied between cell lines (IC50 0.2 –> 10 mM).
AZD0530 inhibited tumor growth in 4/10 xenograft models tested and dynamically
inhibited in vivo phosphorylation of Src substrates paxillin and FAK in both growth-inhibi-
tion-resistant and -sensitive xenografts. The activity of AZD0530 in NBT-II bladder cancer
cells in vitro was consistent with inhibition of cell migration and stabilization of cell–cell
adhesion. These data suggest a dominant anti-invasive pharmacology for AZD0530
that may limit tumor progression in a range of cancers. AZD0530 is currently in Phase II
clinical trials.
ª 2009 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. Introduction best-understood member of a family of nine membrane-The constitutively active protein tyrosine kinase v-Src was
identified as the transforming element of the oncogenic
Rous sarcoma retrovirus more than 30 years ago. Subse-
quently, the oncogenic potential of the normal cellular
homolog c-Src has been revealed (Martin, 2001). Src is theraZeneca, Alderley Park,
.com (T.P. Green).
Development Program
ation of European Biocheassociated, non-receptor tyrosine kinases that also includes
c-Yes and Fyn (reviewed in Thomas and Brugge, 1997). Src
transduces signals that control processes involved in cell pro-
liferation, adhesion, and motility. Most cell types express low
levels of Src; platelets, osteoclasts, and neural cells are the
only normal cell types known to express high levels of SrcMacclesfield, Cheshire, SK10 4TG, UK. Tel.: þ44 1625 516 178;
, National Cancer Institute, Building 562, Fort Detrick,
mical Societies. Published by Elsevier B.V. All rights reserved.
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activation requires dephosphorylation of regulatory tyrosine
527, autophosphorylation of tyrosine 416 within the catalytic
domain, and changes in intramolecular interactions.
Deregulated elevated Src kinase activity has been reported
in a wide range of human tumor types (Frame, 2002; Summy
and Gallick, 2003). Clinical evidence supports a link between
de-regulation of Src activity and tumor progression and me-
tastasis (Talamonti et al., 1993). Through its interaction with
the integrin-binding non-receptor tyrosine kinase focal adhe-
sion kinase (FAK), activated Src mediates the phosphorylation
and recruitment of cytoskeletal proteins such as paxillin to
regulate focal adhesion complexes and cell motility (reviewed
in Playford and Schaller (2004)). It has been demonstrated that
elevated Src activity disrupts the E-cadherin epithelial cell–
cell adhesion system (Avizienyte et al., 2002; Irby and Yeat-
man, 2002) and this can be restored by Src inhibition (Nam
et al., 2002). In a murine model of bladder cancer metastasis,
Src activity was shown to be not required for the growth of
the primary xenograft, but was a critical determinant of me-
tastasis, since the number of mice bearing metastases was
dramatically reduced by the expression of a dominant-nega-
tive mutant of Src (SrcK) or of Csk, the natural cellular nega-
tive regulator of Src (Boyer et al., 2002). These findings support
a hypothesis that a major consequence of aberrant Src signal-
ing in tumor cells is to regulate cell adhesion and facilitate
motility, promoting invasive and metastatic phenotypes.
Studies on fibroblasts engineered to express constitutively
active c-Src (thus mimicking the viral oncogene Src product),
or on fibroblasts deficient in Csk, have clearly demonstrated
that c-Src under these conditions can provide a mitogenic
and transforming drive (Cartwright et al., 1987; Oneyama
et al., 2008; Kmiecik and Shalloway, 1987). However, there is
only very limited evidence supporting mutated, constitutively
active Src in human epithelial cancers (Irby et al., 1999), where
de-regulation appears predominantly driven through post-
translational modifications and intracellular interactions be-
tween Src and various activated transmembrane receptors,
cytoskeletal proteins, and cytoplasmic phosphatases. Src acti-
vated under these cellular conditions in epithelial tumor cells
does not appear to be linked strongly to a mitogenic pheno-
type (in vitro at least), with accumulating evidence suggesting
that the predominant consequence of deregulated Src in tu-
mor cells is to help facilitate a change towards a more aggres-
sive, migratory, and invasive cellular phenotype without
necessarily impacting on cellular proliferation (Boyer et al.,
2002; Jones et al., 2002; Vultur et al., 2008).
The involvement of Src in tumor progression and metasta-
sis has generated considerable interest in Src as a therapeutic
anticancer target. We have reported previously the develop-
ment of AZD0530, a potent, orally available Src inhibitor
(Hennequin et al., 2006). AZD0530 significantly suppressed
the motile and invasive nature of endocrine-resistant breast
cancer cells in vitro, effects which were increased by combina-
tion with the epidermal growth factor receptor (EGFR) inhibi-
tor, gefitinib (Hiscox et al., 2006). Moreover, AZD0530 was
able to restore tamoxifen sensitivity in tamoxifen-resistant
breast cancer cells (Chu et al., 2007).
Here, we report the preclinical pharmacology of AZD0530
with respect to proliferation, migration, and invasion in vitro,and tumor growth, metastasis, and effects on FAK and paxillin
phosphorylation in vivo. We observed inconsistent inhibition
of tumor cell proliferation in vitro and in vivo at therapeutically
achievable concentrations of AZD0530. However, in all tumor
cell types examined, inhibition of Src kinase activity was asso-
ciated with reduced phosphorylation of cellular Src substrates
and inhibition of cell migration. The data support the hypoth-
esis that a key role for Src kinase in tumor progression is the
emergence of an invasive tumor phenotype.2. Results
2.1. In vitro studies
2.1.1. Inhibition of isolated protein kinase activity
AZD0530 potently inhibited Src and the other Src tyrosine
kinase family members investigated (c-Yes, Fyn, Lyn, Blk,
Fgr, and Lck), with high selectivity observed against a panel
of other protein kinases involved in signal transduction
(Table 1), including Csk, the intracellular negative regulator
of Src activation. The only other notable activities observed
were versus Abl (in common with other ATP-competitive Src
inhibitors (Golas et al., 2003; Lombardo et al., 2004)) and versus
activating mutant forms of the EGFR (L858R and L861Q).
2.1.2. Inhibition of cell proliferation
AZD0530 potently inhibited the in vitro proliferation of Src3T3
mouse fibroblasts and demonstrated variable antiproliferative
activity in a range of human cancer cell lines containing
endogenous Src (Table 2). Sub micromolar growth inhibition
of five of the human cancer cell lines tested with AZD0530
(tumor types: colon, prostate, lung, and leukemia) was ob-
served with IC50 values of 0.2–0.7 mM. In 3-day MTS cell prolif-
eration assays (Promega G3580), AZD0530 inhibited in vitro
proliferation of the Bcr–Abl-driven human leukemia cell line
K562 with an IC50 of 0.22 mM.
2.1.3. Inhibition of cell migration
In the microdroplet migration assay, AZD0530 reduced the
migration of human lung cancer A549 cells in a concentra-
tion-dependent manner (IC50 0.14 mM; Figure 1A). AZD0530 at
concentrations of 0.01–0.5 mM demonstrated a clear dose-
dependent antimigratory effect compared with untreated
controls in monolayer scratch assays of human breast cancer
MDA-MB-231 cells (Figure 1B). AZD0530 also dose dependently
inhibited the EGF- and collagen-stimulated migration of NBT-
II bladder cancer cells (Figure 1C). Moreover, at a single con-
centration of 0.25 mM, AZD0530 consistently inhibited migra-
tion in monolayer scratch assays of bladder cancer cell lines
(31%, 37%, and 78% inhibition versus untreated controls in
T24, SCaBER, and 1A6 cell lines, respectively).
2.1.4. Inhibition of cell invasion
AZD0530 treatment significantly impaired the invasion of
HT1080 cells through a 3-dimensional (3D) collagen matrix
(Figure 1D). In contrast to other 3D invasion assays, our assay
(see Methods) monitors the proportion of total cells within
a 3D matrix invading beyond a specified depth (60 mm),
thereby distinguishing repressed cellular invasion from cell
Table 1 – Inhibitory activity of AZD0530 on isolated tyrosine
kinases. IC50 values are the mean of at least three measurements.
Kinase Definition Mean IC50, nM
c-Src Ubiquitous Src family member 2.7
Lck Immune cell-restricted
Src family member
<4
c-Yes Ubiquitous Src family member 4
EGFR L861Q Activating mutation
of epidermal growth
factor receptor
4
Lyn Immune cell-restricted
Src family member
5
EGFR L858R Activating mutation
of epidermal growth
factor receptor
5
Fyn Ubiquitous Src family member 10
Fgr Immune cell-restricted
Src family member
10
Blk Immune cell-restricted
Src family member
11
v-Abl Viral Abelson
tyrosine kinase
30
EGFR Epidermal growth
factor receptor tyrosine kinase
66
c-kit Stem cell
factor receptor tyrosine kinase
200
EphA2 Ephrin receptor
tyrosine kinase
236
Csk c-terminal Src kinase
(negative regulator of Src)
>1000
PDGFRb Platelet-derived growth
factor receptor tyrosine kinase
>5000
PDGFRa Platelet-derived growth
factor receptor tyrosine kinase
10,000
CDK2 Cyclin-dependent kinase 2 10,000
Flt-4 (VEGFR3) Fms-like tyrosine
kinase 4
>10,000
FGFR (FGFR1) Fibroblast growth
factor receptor tyrosine kinase
>10,000
AUR-3 Aurora kinase-3 >10,000
MEK Mitogen-activated protein kinase 14,000
KDR (VEGFR2) Kinase insert
domain-containing receptor
21,000
Flt-1 (VEGFR1) Fms-like tyrosine
kinase 1
>100,000
AZD0530 (10 mM) was also tested for inhibitory activity versus
a panel of serine/threonine kinases using a filter capture assay
with 32P and showed <20% inhibition of activity (n¼ 23).
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or excessive cell death. This method confirms that AZD0530
exposure produces a significant and dose-dependent inhibi-
tion of the invasive properties of HT1080 cells.
2.1.5. Inhibition of cell scattering
AZD0530 1 mM completely inhibited EGF-induced cell scatter-
ing in NBT-II bladder cancer cells, restoring cell–cell adhesion
and the localization of desmoplakin to desmosomal junctions
(Figure 2A).
2.1.6. Inhibition of paxillin phosphorylation
AZD0530 dose dependently inhibited phosphorylation of the
Src substrate paxillin in NBT-II bladder cancer cells
(Figure 2B). Moreover, AZD0530 treatment (1 mM) induceda relocalization of paxillin from the cell membrane into the
cell cytoplasm (Figure 2C) further supporting a role for Src in
the early development of cell migratory behavior.
2.1.7. Effects on the EGFR
Given the moderate inhibitory effect observed for AZD0530
against the EGFR in the isolated kinase assay (IC50 66 nM; Ta-
ble 1), further studies were performed to investigate
AZD0530 effects on the EGFR. In a head-to-head assay measur-
ing EGFR phosphorylation in KB cells, AZD0530 exhibited an
IC50 of 1.25 mM compared with 11 nM for gefitinib, an EGFR
tyrosine kinase inhibitor. In isolated kinase assays, AZD0530
exhibited IC50s of 5 and 4 nM respectively, for EGFR point-
mutant isoforms L858R (Millipore 14-626) and L861Q (Millipore
14-627). Effects on the EGFR L858R isoform were further inves-
tigated in PC-9 cells, a non-small-cell lung cancer (NSCLC)
cell line harboring this EGFR mutation. AZD0530 inhibited
growth of PC-9 cells with an IC50 of 0.23 mM in 3-day MTS cell
proliferation assays (Promega G3580).
2.1.8. Enzyme kinetics
Pre-incubation of Src kinase with 100 nM AZD0530 (in the
presence of 160 mM ATP) resulted in >95% inhibition of Src
activity. A subsequent 10-fold dilution to 10 nM AZD0530 in
the presence of a high concentration of ATP (1.60 mM) led to
a regain of Src activity, with only 30% inhibition, suggesting
that inhibition was reversible. A similar degree of inhibition
was observed for the same final concentrations of AZD0530
and ATP without the dilution step.
The reversibility studies implied that AZD0530 was com-
petitive with ATP, as has been reported for other anilinoquina-
zolines (Bridges, 2001). ATP-competitive inhibition was
confirmed in experiments where both the concentration of
ATP and that of AZD0530 were varied at fixed concentrations
of the substrate, Src II peptide. The estimated inhibition con-
stant, Kis was 1.5 and the 95% confidence interval (CI) was
1.2, 1.9 nM. This is lower than the IC50 of 2.7 nM reported in
Table 1 because it relates to a situation in the absence of com-
peting ATP. AZD0530 was shown to follow pure noncompeti-
tive kinetics when the concentration of Src II peptide was
varied at 250 mM ATP, with an apparent Ki0 of 10 nM (95% CI
8.4, 12.0; Figure 3A and B), which corresponds to a Ki of
1.1 nM (95% CI 0.9, 1.3) in the absence of ATP. Many kinases
have structural differences between their active and inactive
forms (Huse and Kuriyan, 2002). Inactivated Src adopts
a closed conformation and AZD0530 binds approximately
10-fold more weakly to inactive Src (Kd 11 nM; 95% CI 9.3, 14).2.2. In vivo studies2.2.1. Pharmacokinetics
The AZD0530 plasma concentration 6 h after oral dosing
increased proportionally to the dose (Figure 4A).
2.2.2. Src3T3 allografts and xenografts
AZD0530 treatment potently inhibited the proliferation of
subcutaneously transplanted Src3T3 fibroblasts in mice
(Figure 4B) and rats (Hennequin et al., 2006) in a dose-depen-
dent manner. In both models, significant inhibition of tumor
Table 2 – Inhibitory activity of AZD0530 on cell line proliferation. IC50 values are the mean of at least three measurements.
Cell line Origin Source Culture conditions AZD0530 IC50 (mM)
Src Y530F NIH 3T3 Mouse embryo Sydonia Rayter,
Sugen, Inc.
DMEMþ 10% FCSþ 1% L-glutamine 0.08
Calu-6 Human NSCLC ATCC HTB-56 RPMI 1640þ 10% FCS >10
A549 Human NSCLC ATCC CCL-185 DMEMþ 10% FCS 14
LoVo Human colon ATCC CCL-229 DMEMþ 10% FCSþ 1% L-glutamine 0.2
SW 403 Human colon ECACC 87071008 L-15þ 10% FCS 0.6
HT29 Human colon ECACC 85061109 EMEMþ 5% FCSþ 1% NEAA 6
HCT 116 Human colon ATCC CCL-247 McCoy’s 5aþ 10% FCS >10
PC-3 Human prostate ATCC CRL-1435 RPMIþ 10% FCSþ 10% M1 0.7
K562a Human Phþ leukemia Paterson Laboratories,
Christie Hospital, Manchester, UK
RPMI 1640þ 10% FCS 0.2
SKOV-3 Human ovary ATCC HTB-77 Ham’s F-12þ 10% FCS >10
BT474C Human breast Vall d’Hebron University
Hospital, Barcelona, Spain
DMEMþ 10% FCSþ 1% L-glutamine 1.6
MDA-MB-231 Human breast ATCC HTB-26 DMEMþ 10% FCSþ 1% L-glutamine 3
MCF-7 Human breast Dr W. Heuse,
Cancer Research UK, London, UK
DMEMþ 10% FCSþ 1% L-glutamine >10
PC-9a Human NSCLC Professor K. Nishio,
National Cancer Center
Hospital, Tokyo, Japan
RPMI 1640þ 10% FCS 0.23
ECACC, European Collection of Cell Cultures; NEAA, non-essential amino acids; NSCLC, non-small-cell lung cancer.
a 3-day MTS assay.
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mice [P< 0.01] and 98% inhibition in rats [P< 0.001] versus an-
imals treated with vehicle) and, at the maximum doses inves-
tigated, complete tumor growth inhibition was observed
(100% inhibition at 25 mg/kg/day in mice and 10 mg/kg/day
in rats) (Hennequin et al., 2006).
2.2.3. Human tumor xenografts
Once-daily oral dosing of AZD0530 resulted in a moderate
growth delay in 4/10 xenograft models tested (Table 3). In
the remainder of the xenograft panel, AZD0530 treatment
failed to inhibit primary tumor growth. Representative
xenograft growth delay curves for an AZD0530 growth-inhibi-
tion-sensitive (Calu-6) and an AZD0530 growth-inhibition-
insensitive model (LoVo) are shown in Figure 4C and D,
respectively. AZD0530 did not affect any aspect of tumor
vascularity in xenograft models as assessed by blood vessel
number or CD31 positive vessels (data not shown).
2.2.4. NBT-II bladder cancer metastasis model
In nude mice bearing subcutaneous xenografts of NBT-II
bladder cancer cells, once-daily AZD0530 treatment at doses
of 10, 25, and 50 mg/kg/day resulted in a small, non significant
delay in xenograft growth at the highest dose only (50 mg/kg/
day; Figure 4E). In contrast, all three doses of AZD0530 resulted
in a reduction in the number of mice from which tumor colo-
nies could be grown from mesenteric lymph node extracts
(Figure 5A). In an additional experiment, this antimetastatic
effect of AZD0530 did not appear to be affected by a 7-day
delay between cell inoculation and drug administration. One
out of seven mice developed metastases in a group that
started treatment with AZD0530 50 mg/kg/day 7 days after
tumor cell inoculation, and 1/7 developed metastases in
a group that started treatment with the same dose immedi-
ately after cell inoculation.2.2.5. Phosphorylation of Src kinase substrates FAK and
paxillin
Levels of phosphorylated FAK (pY861) and paxillin (pY31),
assessed by immunohistochemistry using phosphospecific
antibodies, were reduced markedly in tumors from animals
bearing both growth-inhibition-sensitive and growth-inhibi-
tion-insensitive xenografts after 14–28 days’ treatment with
AZD0530 50 mg/kg/day (Figure 5B–D). Antibodies detecting
non-phospho epitopes of FAK or paxillin showed no effect
on the expression of either protein (data not shown).3. Discussion
The discoveries of the first oncogenic kinase, v-Src, and its
cellular homolog, Src, have led to significant progress in our
understanding of the biochemistry of both normal and malig-
nant cells (Martin, 2001). Substantial evidence implicates
deregulated Src in the development of solid tumors, and Src
inhibition is a potential therapeutic strategy in many common
cancers (Frame, 2002; Summy and Gallick, 2003). In addition,
Src activity is essential for osteoclast bone resorptive activity,
suggesting that Src inhibitors could have an additional benefit
in the management of malignant bone disease (Metcalf et al.,
2002).
The present studies investigated the preclinical properties of
the novel Src inhibitor AZD0530. Isolated enzyme assays dem-
onstrated that AZD0530 is a potent, reversible, Src inhibitor
that has high selectivity when compared with a range of protein
tyrosine kinases involved in signal transduction. Inactivation of
Src by AZD0530 is achieved by competitive binding of AZD0530
to an ATP site (Hennequin et al., 2006; Noble et al., 2004), and is
consistent with the crystal structure of a complex of AZD0530
with inactivated Src. AZD0530 affinity for activated Src is
Figure 1 – AZD0530 antimigratory and anti-invasive activity. (A) An illustration of the microdroplet migration assay. The image shows human
NSCLC A549 cells migrating out from an agarose microdroplet after 72 h of culture, and indicates how cell migration is measured. (B)
Representative time-lapse photography images (magnification 3200) in which AZD0530 shows dose-dependent antimigratory activity compared
with untreated controls in human breast cancer cells (MDA-MB-231) after 18 h treatment in a monolayer scratch assay. (C) AZD0530 exhibited
dose dependent inhibition of NBT-II cell motility. EGF (20 ng/mL)- and collagen-induced cell motility assessed by videomicroscopy in vitro
(meanD SEM of at least three experiments). (D) In vitro invasion of HT1080 cells through a 3D fibrillar collagen matrix. Exposure of HT1080
cells to AZD0530 resulted in a dose-dependent reduction in the proportion of cells invading beyond a depth of 60 mm into a 3D collagen type I
matrix. Bars represent mean ± SEM of three experiments. Representative images (magnification 3200) of invaded, Hoechst-labeled cells at a depth
of 60 mm into the 3D collagen matrix are shown.
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Figure 2 – AZD0530 effects on cell scattering and paxillin phosphorylation. (A) AZD0530 inhibited EGF (20 ng/mL)-mediated loss of
desmoplakin immunoreactivity from the surface of NBT-II cells in monolayer culture. (B) AZD0530 inhibited tyrosine phosphorylation of paxillin
Y118 in NBT-II cells in vitro. Relative phosphorylation levels were quantified by densitometry. (C) Effects of AZD0530 on the intracellular
distribution of phosphorylated paxillin in NBT-II cells in vitro.
MO L E C U L A R O N C O L O G Y 3 ( 2 0 0 9 ) 2 4 8 – 2 6 1 25310-fold higher than for inactivated Src. This observation could
explain the inconsistent abrogation of Src autophosphorylation
(pY419)observedinWesternblotsafter treatmentwith AZD0530
in preclinical models (data not shown). Subsequent studies
focused on downstream substrates of Src (FAK and paxillin)
and confirmed these as more consistent biomarkers of Src tyro-
sine kinase and AZD0530 pharmacodynamic activity.AZD0530 caused a dramatic inhibition of human non-
small-cell lung (A549) and human breast (MDA-MB-231) can-
cer cell migration in vitro at concentrations well below the
antiproliferative IC50 values in these two cell lines. In migra-
tion scratch assays using a range of human tumor cell lines,
consistent antimigratory activity was seen using a single con-
centration of 250 nM AZD0530. Furthermore, in NBT-II bladder
Figure 3 – AZD0530 enzyme kinetics. (A) Competitive kinetics when
the concentrations of AZD0530 and ATP are varied in the presence
of 1 mM Src II peptide, with best-fit values of Kis 1.5 nM, maximum
velocity (Vmax) 0.03 mM/min, and ATP KM 190 mM. (B) Pure
noncompetitive kinetics when the concentrations of AZD0530 and
Src II peptide are varied in the presence of 1.6 mM ATP, with best-fit
values of apparent Ki0 10 nM; Vmax 0.04 mM/min, and Src peptide II
KM 330 mM.
M O L E C U L A R O N C O L O G Y 3 ( 2 0 0 9 ) 2 4 8 – 2 6 1254cancer cells, inhibition of cell migration in response to treat-
ment with AZD0530 was accompanied by reduced phosphor-
ylation of the Src substrate paxillin, which has previously
been shown to be critically required for cell migration (Boyer
et al., 1997; Valles et al., 2004). These data are consistent
with the well-established role of Src in cell migration, and fur-
ther support the association of Src activity with an invasive
tumor cell phenotype. Inhibition of Src activity also inhibited
the invasion of HT1080 cells into matrigel or collagen in a 3D
invasion assay. Although the invasion of HT1080 cells into
3D fibrillar collagen gels was inhibited by diverse protease
inhibitors, a compensatory mechanism, the so-called mesen-
chymal to amoeboid transition, required treatment with an
inhibitor cocktail targeting multiple extracellular proteases
including, matrix metalloproteinases, and serine proteases
to be fully effective (Wolf et al., 2003; Friedl and Wolf, 2003).
Such tumor plasticity permits continued invasion through3D collagen in the presence of these inhibitors and may in
part explain the failure of MMP inhibitors to impede tumor
progression in clinical trials. In contrast, the data obtained
with AZD0530 indicate that in HT1080 cells, which are known
to express both MMP and serine proteases, inhibition of Src ki-
nase circumvents such compensatory responses, suggesting
that inhibitors of Src kinase target an integral component or
multiple components of the invasive process, and may pres-
ent significant utility as an anti-invasive therapy in vivo.
AZD0530 demonstrated in vitro and in vivo antiproliferative
activity against Src3T3 fibroblasts that overexpress a constitu-
tively active form of Src. The effect of AZD0530 on the growth
of human cancer cell lines and tumor xenografts expressing
endogenous Src was more variable and generally modest
in comparison with the Src3T3 model. The transforming,
mitogenic properties of both v-Src and constitutively active
c-Src in fibroblasts suggest that high endogenous Src activity
could provide a mitogenic drive in human epithelial cancer
cells. However, published data do not support a direct associ-
ation of Src kinase activity with cell proliferation, and suggest
that low, rather than high, levels of activated Src may be a de-
terminant of growth sensitivity to Src inhibitors (Emaduddin
et al., 2008; Jones et al., 2002; Rosen et al., 1986). Our data
further highlight the lack of correlation between the inhibition
of proliferation in vitro and inhibition of xenograft growth in
vivo. For example, treatment of Calu-6 (NSCLC) cells with
AZD0530 in vitro resulted in minimal antiproliferative activity
(IC50> 10 mM, Table 2) whereas the growth of Calu-6 xeno-
grafts in vivo was inhibited by w50% (although no dose–
response relationship was observed). In the case of the colon
cancer cell lines HT29 and LoVo, which have relatively high
and low Src kinase activity, respectively (Bolen et al., 1987;
Emaduddin et al., 2008), sensitivity to AZD0530 in vitro segre-
gated with low Src activity. Although no inhibition of in vivo
tumor growth was observed for either of these cell lines,
Src kinase activity was clearly inhibited as evidenced by the
reduced phosphorylation of Src kinase substrates FAK and
paxillin (Figure 5). Taken together these data suggest that
both cellular context (in vitro versus in vivo setting) and cell-
line-specific Src kinase activity and signaling may determine
response to Src kinase inhibitors, rather than direct inhibition
of a Src mitogenic phenotype.
The growth delay observed in vivo was not attributable to an
anti-angiogenic effect, as blood vessel density staining was not
affected in the AZD0530-treated animals (data not shown). Pos-
sible explanations for the anti-growth activity observed are (a)
an indirect effect on growth by AZD0530 through inhibition of
local migration and invasion of the tumor cells, or (b) an as yet
unknown underlying molecular phenotype, possibly influenced
by Src kinase dependent aspects of the tumor and host microen-
vironment that contribute to local regulation of tumor growth.
In the three human colon tumor xenograft models investigated,
AZD0530 had no effect on tumor growth, but immunohisto-
chemistry revealed that AZD0530 was biologically active, as
shown by the inhibition of FAK and paxillin phosphorylation
on tyrosine residues known to be direct targets for Src kinase.
Although Src kinase activity has been suggested to support an-
giogenic behavior in endothelial cells (Eliceiri et al., 1999;
Lesslie and Gallick, 2005) we were unable to demonstrate any
effect of Src kinase inhibition on tumor vasculature in xenograft
Figure 4 – AZD0530 pharmacokinetics and effects on xenograft tumor growth. (A) AZD0530 plasma concentration (ng/mL) 6 h post-terminal
dose in female nude mice bearing LoVo tumors (n[ 7 per group). (B–D) Effect of once-daily AZD0530 on tumor growth in female nude mice
(n[ 7 per group) bearing (B) Src3T3 allografts, (C) human NSCLC (Calu-6) xenografts, and (D) human colon cancer (LoVo) xenografts. (E)
Effects of AZD0530 at 10 (n[ 14), 25 (n[ 14) or 50 mg/kg/day po (n[ 7) on the same day as cell inoculation or 1 week after inoculation on the
growth of NBT-II tumor cells grown as sc xenografts in nude mice. Mean ± SEM.
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factor targeted agents (Calu-6, data not shown). Taken together,
these data support the hypothesis that Src is acting primarily to
promote invasive tumor progression in the majority of solid
tumor types. These data are consistent with previously reported
data for dasatinib, a Src/Abl inhibitor, which inhibits integrin-mediated motility and adhesion in colorectal cancer cell lines
(Serrels et al., 2006), and migration and invasion of sarcoma
cell lines (Shor et al., 2007).
In isolated kinase assays, AZD0530 inhibited the EGFR with
approximately 20-fold lower potency than its effects on Src.
Functional assays in cell culture showed only modest effects
Table 3 – Effect of once-daily AZD0530 50 mg/kg on human tumor cell xenograft growth in female nude mice.
Cell line Origin Total number
of cells inoculated
Average tumor
volume before
randomization
(cm3)
Number of mice randomized
to each group
(treatment/control)
Duration of
dosing (days)
Mean inhibition
of tumor volume
relative to
control (%)
MDA-MB-231 Breast ER 5 106 0.062 9/9 27 40
AsPc-1 Pancreas 1 107 0.3 10/10 15 42
Calu-6 Lung 1 106 0.2 7/8 28 40–50a
BT474C Breast ERþ 1 107 0.4 12/15 21 23–34b
ZR-75-1 Breast ERþ 1 107 0.5 10/10 15 None
Colo205 Colon 3 106 0.3 9/9 18 None
KB Oral carcinoma 5 106 0.3 8/8 10 None
HT29 Colon 1 107 NA 10/10 36–91 None
LoVo Colon 1 107 0.3 7/8 14 None
HPAC Pancreas 1 107 0.3 15/15 21 None
EMEM, Earle’s minimal essential medium; NA, not applicable, treatment started on day of inoculation.
a Range of means observed across eight separate studies.
b Range of means observed across two separate studies.
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potent effects on the EGFR activating point mutants L858R
and L861Q. These results are consistent with recent findings
that AZD0530 inhibited proliferation and migration more po-
tently in NSCLC cell lines harboring mutant EGFR isoforms
than in NSCLC cell lines harboring wild-type EGFR (Helfrich
et al., 2006). Mutations in the EGFR that modulate sensitivity
of cancers to EGFR inhibitors can also modulate sensitivity to
Src inhibition (Fu et al., 2008; Song et al., 2006), raising the pos-
sibility of additional utility of AZD0530 in cancers harboring
mutant EGFR.
AZD0530 exhibited moderate activity against Abl kinase
in the isolated kinase assay. Affinity for Abl appears to
be a common characteristic of the small-molecule ATP-
competitive Src inhibitors, although this effect is smaller
with AZD0530 than with dasatinib and bosutinib (Golas
et al., 2003; Lombardo et al., 2004). Moreover, AZD0530
exhibited moderate effects (IC50 0.22 mM) in a functional assay
of Abl inhibition using human leukemia cells that are growth
driven through Bcr–Abl activity. In contrast, dasatinib and
bosutinib demonstrated IC50 values of 1 nM and 20 nM,
respectively, for growth inhibition in the same cells (Manley
et al., 2005). AZD0530’s activity at Abl is not currently consid-
ered sufficient to provide a strong rationale for its clinical
development in Bcr–Abl-driven leukemias.
Further investigation of AZD0530 in other tumor models
is warranted to define its biochemical and anticancer activity.
In the current study, AZD0530 was tested for tumor growth
inhibitory activity in the xenograft models available at the
time, and this did not provide a complete overlap with the
panel of cell lines tested for AZD0530 antiproliferative effects
in vitro. However, it is likely that tumor models that assess the
antiproliferative activity of a test compound against a cancer
cell line or a primary tumor subcutaneous xenograft will
have limited value in assessing the activity of an anti-invasive
agent. Such agents may provide benefit in terms of inhibiting
local invasive growth or metastatic spread of an established
cancer, rather than reducing primary tumor growth per se.
Indeed, Src inhibition has recently been shown to significantlyreduce metastasis in xenograft models of pancreatic, bladder,
and colorectal cancer (Green et al., 2005; Phillips et al., 2007;
Trevino et al., 2006).
The data presented here support a mechanistic role of en-
dogenous Src in promoting an invasive cell phenotype
through the regulation of cell adhesion, migration, and inva-
sion. AZD0530 inhibited cancer cell proliferation in vitro and
in vivo in a constitutively active Src fibroblast tumor model,
and in some human tumor cell lines. The lack of consistent
antiproliferative activity and the underlying mechanism
of such diverse responses require further investigation in
additional tumor models. Effects on models of invasion were
more clear cut: AZD0530 inhibited invasion and migration of
cancer cells in vitro, and inhibited phosphorylation of proteins
controlling migration in vitro and in vivo. In an in vivo model of
bladder cancer metastasis, AZD0530 inhibited the number of
lymph node metastases, detected through colony forming as-
says, thus recapitulating the effects seen with dominant-neg-
ative Src and Csk constructs in earlier studies in this model
(Boyer et al., 2002). We and others have recently demonstrated
activity of AZD0530 in inhibiting metastasis in pancreatic
cancer models (Green et al., 2005) and in an orthotopic model
of human colorectal carcinoma (Phillips et al., 2007). Together
with the results presented here, these data suggest that
AZD0530 may provide clinical benefit by preventing or
delaying tumor progression through inhibition of tumor cell
migration and invasion. AZD0530 is currently in Phase II
clinical trials.4. Experimental procedures
4.1. Isolated protein kinase assay
Inhibition of tyrosine kinase activity was examined
using an enzyme-linked immunosorbent assay (ELISA)
with recombinant catalytic domains of a panel of receptor
and non-receptor tyrosine kinases (in some cases only
Figure 5 – AZD0530 effects on metastasis and phosphorylation of Src substrates FAK and paxillin. (A) Effects of increasing doses of AZD0530 on
metastasis to lymph nodes after injection of NBT-II cells into nude mice. (B–D) Immunohistochemical analysis after 28 (Calu-6) or 14 (LoVo)
days once-daily oral treatment with vehicle alone or AZD0530 50 mg/kg. AZD0530 inhibited phosphorylation of paxillin (pY31) in (B) human
Calu-6, and (C) LoVo xenografts grown subcutaneously in nude mice. (D) AZD0530 inhibited phosphorylation of FAK (pY861) in LoVo human
xenografts grown subcutaneously in nude mice. Images are at magnifications of (B) 340 and (C and D) 320.
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been described previously (Ple´ et al., 2004). AZD0530 dose
ranges varied depending on the activity versus the particular
kinase tested, but were typically 0.001–10 mM.
Specificity assays against a panel of serine/threonine
kinases were performed using a filter capture assay with 32P.
Briefly, multidrop 384 plates containing 0.5 mL AZD0530 or
controls (dimethyl sulfoxide [DMSO] alone or pH 3.0 buffer
controls) were incubated with 15 mL of enzyme plus peptide/
protein substrate for 5 min before the reaction was initiated
by the addition of 10 mL of 20 mM Mg.ATP. For all enzymes
the final concentration was approximated to the Michaelis
constant (Km). Assays were carried out for 30 min at room
temperature before termination by the addition of 5 mL ortho-
phosphoric acid. After mixing, the well contents were har-
vested onto a P81 Unifilter plate, using orthophosphoric acid
as the wash buffer. Microcal Origin software (vs. 3.78, MicrocalSoftware, Inc., Northampton, MA, USA) was used to interpo-
late IC50 values by nonlinear regression.
4.2. Cell lines
The cell lines used were mouse NIH 3T3 fibroblasts engineered
to overexpress a constitutively active form of human Src
(Src3T3) with a point mutation at the negative regulatory tyro-
sine site in the c-terminal domain (Y530F) (Ple´ et al., 2004) and
human cancer cell lines containing endogenous Src (Table 2).
Src3T3 fibroblasts form colonies in soft agar and grow subcu-
taneously in immunocompromised athymic rats and mice in
vivo, while the wild-type parental 3T3 cells do not. Src3T3 cells
will grow in medium containing as little as 0.5% fetal calf
serum (FCS; used in the assay conditions), whereas wild-
type non-Src-transfected 3T3 cells will not grow in these low
serum conditions. AZD0530 functional activity against Abl
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K562 human leukemia cells known to be growth driven
through Bcr–Abl activity (Lozzio and Lozzio, 1975). NBT-II rat
bladder cancer cells were sourced and cultured as described
previously (Boyer et al., 2002).4.3. Cell proliferation assay
Cell proliferation was assessed using a colorimetric 5-bromo-
20-deoxyuridine (BrdU) Cell Proliferation ELISA kit (Roche
Diagnostics GmbH), as described previously (Ple´ et al., 2004).
Briefly, cells were plated onto 96-well plates (1.5 104 cells/
well), the following day 0.039–20 mM AZD0530 in DMSO (at
a final concentration of 0.5%) was added and the cells were
incubated for 24 h. The cells were pulse labeled with BrdU
for 2 h and fixed. Cellular DNA was then denatured with the
provided solution and incubated with antiBrdU peroxidase
for 90 min. Following three washes with phosphate-buffered
saline, tetramethylbenzidine substrate solution was added
and the plates were incubated on a plate shaker for
10–30 min until the positive control absorbance at 690 nm
was approximately 1.5 absorbance units.4.4. EGFR phosphorylation assay
KB (nasopharyngeal carcinoma) cells were seeded at
5000 cells/well in 96-well plates and cultured for 72 h in Rose-
well Park Memorial Institute (RPMI) 1640 media with 10% FCS,
followed by 24 h’ incubation with serum-free RPMI 1640. Cells
were treated with compound for 90 min at concentrations
ranging from 0 to 10 mM. Cells were incubated with 15 ng/
mL EGF ligand (concentration required to increase receptor
phosphorylation to 90% of maximum) for 5 min prior to lysis.
Levels of phosphorylated EGFR were measured using the hu-
man phospho-EGFR Duoset ELISA kit (R&D Systems,
DYC1095).4.5. Microdroplet migration (chemokinesis) assay
The microdroplet migration assay assesses the ability of test
compounds to inhibit the random motility (chemokinesis) of
human epithelial A549 lung cancer cells (American Type Cul-
ture Collection [ATCC] CCL 185), which were routinely cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)þ 10%
FCS. The assay method has been described in full previously
(Ple´ et al., 2004). Briefly, A549 cells (2 107/mL) were sus-
pended in warm DMEM (37 C) containing 0.3% agarose. The
suspension was pipetted into 96-well plates (2 mL/well) and
chilled briefly on ice to allow the agarose microdroplet to
gel. When set, 90 mL of chilled RPMI 1640 medium (Gibco Invi-
trogen Cell Culture, Paisley, UK) was added to each well,
followed by 10 mL AZD0530 (0.02–5 mM). The plates were
incubated for 72 h at 37 C to allow migration to occur. Cell
migration was measured by taking several equidistant
measurements from around the agar droplet to the migrating
front of the motile cells. An illustration of the microdroplet
migration assay is shown in Figure 1A, indicating how cell
migration was measured.4.6. Monolayer scratch assay
Human MDA-MB-231 breast cancer cells and T24, SCaBER,
and 1A6 bladder cancer cells were grown as monolayers in
adapted six-well tissue culture plates. Confluent monolayers
were gently scraped with a sterile pipette tip to form
a scratch and AZD0530 (0.01–0.5 mM) was added to the wells
in medium (phenol red-free DMEM [Gibco Invitrogen Cell
Culture] supplemented with 10% charcoal/dextran-treated
FCS and 1% L-glutamine). Cell movement back into the area
of the scratch was recorded by time-lapse photography
over 18 h.
4.7. NBT-II cell adhesion and migration assays
The effects of AZD0530 on EGF- and collagen-induced motility
of NBT-II cells were assessed by videomicroscopy as described
previously (Valles et al., 2004). The effect of AZD0530 on
EGF-induced cell dispersion was evaluated by immunofluo-
rescence with anti-desmoplakin antibodies to monitor the
EGF-induced loss of desmosomes from the cell periphery, as
reported before (Boyer et al., 1997).
4.8. Assessment of paxillin phosphorylation
The effects of AZD0530 on paxillin phosphorylation was
assessed in NBT-II cells that had been stimulated with
100 ng/mL EGF for 15 min in the presence of increasing
amounts of AZD0530. Paxillin tyrosine phosphorylation was
revealed by immunoblotting with polyclonal antibodies
against phospho Y118-paxillin and total paxillin.
4.9. 3D invasion assay
Fibrillar collagen type I gels (1 mg/mL final concentration)
were prepared by neutralizing a solution of collagen type I
(Vitrogen 100, Cohesion Corp.) with 1/10 volume 10 DMEM
concentrate, diluted to a final concentration of 1 with dis-
tilled H2O, to which 1/11 volume 0.1 N NaOH was added.
Fibrillar collagen gels (80 mL) were set within the upper cham-
ber of a 24-well transwell insert, above an 8 mm pore-size pol-
ycarbonate filter (Costar, Corning Inc.) at 37 C for 18 h prior
to cell seeding. Human HT1080 fibrosarcoma cells (ATCC CCL
121; DMEM [Gibco Invitrogen Cell Culture], supplemented
with 0.2% FCS and 2 mM L-glutamine) were seeded on top
of a collagen gel in an upper transwell chamber (1 104 cells
per transwell). DMEM supplemented with 10% FCS and 2 mM
L-glutamine (750 mL total volume) was placed in the lower
chamber to provide a chemotactic gradient. AZD0530 (0.1,
1, and 10 mM) or vehicle (0.1% DMSO) was added to the cells
prior to seeding and also to media within the lower chamber.
Transwells were incubated at 37 C for 72 h and then incu-
bated with 10 mM Hoechst 33342 (Molecular Probes Europe)
in serum-free DMEM for 30 min at 37 C. Invading cells
were visualized by confocal microscopic analysis using
a Bio-Rad Radiance 2000 multiphoton confocal illumination
unit attached to a Nikon Eclipse inverted microscope. Quan-
tification of cell invasion was performed with modification to
the protocol as described previously (Carragher et al., 2006).
Briefly, using a 20 objective, optical sections were scanned
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analysis software (Media Cybernetics) was applied to identify
the number of positive pixels (Hoechst stain above a thresh-
old) and segment into individual nuclei per optical section.
The accumulated sum of the positive nuclei present in the
optical sections between 60 and 200 mm below the top of col-
lagen gels was expressed as a percentage of the total number
of positive nuclei on top and within the collagen gel. This
value, therefore, represents the proportion of total cells
within each sample invading beyond a depth of 60 mm and
up to 200 mm.
4.10. Enzyme kinetics
Investigation of the reversibility and the mechanism of
AZD0530 inhibition was conducted using a full-length acti-
vated human Src (phosphorylated at tyrosine 416, Upstate Bio-
tech, Dundee, UK) in a continuous, coupled assay adapted
from Jenkins (1991). ATP and peptide substrate (Src II peptide;
Merck Bioscience, Darmstadt, Germany) concentrations were
varied in turn (ATP 40–1280 mM; Src II peptide 100–800 mM), in
conjunction with AZD0530 (0–30 nM), at saturating concentra-
tions of the non-varied substrate (ATP 1.6 mM; Src II peptide
1.0 mM). The binding affinity of AZD0530 for inactivated Src
(phosphorylated at tyrosine 527, not tyrosine 416) was mea-
sured using a BIAcore inhibition-in-solution assay (Karlsson
et al., 2000). The assay followed competition binding between
AZD0530 and an immobilized ureidoquinazoline (Sullivan
et al., 2005) for binding to Src. Data analysis was performed
by unweighted nonlinear regression using GraFit, version 5
(Erithacus Software Ltd, Horley, UK) and an F-test (Mannervik,
1982) was used to identify the most suitable equation.
4.11. Xenograft studies
Female athymic mice (nu/nu: Alpk; Alderley Park) and rats (RH-
rnu/rnu; Harlan, France) were housed and maintained as previ-
ously described (Wilkinson et al., 2007). All animal studies
were conducted in accordance with the UK Home Office Animal
(ScientificProcedures) Act 1986and French Ministries ofAgricul-
ture and Research (Directive N86/609 CEE du 24 Nov. 1986).
Src3T3 and human tumor lines (as indicated in Table 3) were in-
oculated subcutaneously in the left flank of animals. Tumor
growth was monitored by bi-dimensional caliper measure-
ments twice weekly. The tumor volume was calculated by the
following formula: (lengthwidth) O(lengthwidth) (p/6)
and supported by excision and weighing of tumors at the end
of the studies. Dosing started when the average tumor volume
reached 0.2–0.5 cm3 (except MDA-MB-231 and HT29; see Table
3). Animals were treated once daily by oral gavage with either
vehicle alone or AZD0530 6.25–50 mg/kg for 10–91 days (Table
3). Tumor growth inhibition was calculated as described previ-
ously (Wedge et al., 2005). For pharmacokinetic and pharmaco-
dynamic analysis animals were humanely sacrificed and
samples (plasma and tumor) were collected. Tumor samples
were homogenized with 5 volumes of water and extracted
with chloroform. Plasma and tumor samples were analyzed
for AZD0530 concentration using high-performance liquid chro-
matography with tandem mass spectrometric detection after
solid-phase extraction.4.12. Metastasis studies
Female nude mice (nu/nu Swiss strain) aged 7 weeks old were
injected subcutaneously with 5 106 NBT-II cells. Treatment
with AZD0530 at 10 (n¼ 14), 25 (n¼ 14) or 50 mg/kg/day po
(n¼ 7) was initiated on the same day as cell inoculation. In
an additional cohort of seven mice, treatment with AZD0530
50 mg/kg/day po was initiated one week after inoculation.
Treatment with AZD0530 continued for 2 months. Control
mice received vehicle alone. Tumor growth was assessed
weekly by measuring two perpendicular diameters with a cal-
iper. Tumor volume (V) was calculated as follows: V¼ a2 b/2
where a¼ tumor width (mm) and b¼ tumor length (mm).
When the tumors reached a volume of 1500–2000 mm3, the
mice were sacrificed and lymph nodes harvested. The pres-
ence of macroscopic metastases in the lymph nodes, liver,
and lungs was assessed at autopsy. To assess the presence
of micrometastases, fragments of lymph nodes or other or-
gans (liver, lungs) were placed into culture and examined mi-
croscopically at various times after seeding for the presence of
epithelial foci derived from metastatic cells.
4.13. Immunohistochemistry
Sections of paraffin-embedded xenograft tissue (4 mm) were
dewaxed and heated in a pressure cooker in high-pH EDTA
buffer for antigen retrieval. Endogenous peroxidase activity
was blocked using H2O2, and sections were incubated in
buffer containing normal goat serum to minimize non-spe-
cific protein binding. Sections were incubated with primary
antibody (0.5 mg/mL rabbit polyclonal IgG anti-FAK [pY861],
Biosource UK #44-626; or 1.22 mg/mL rabbit polyclonal IgG
anti paxillin [pY31], Biosource UK #44-720) for 1 h at room
temperature, followed by washing and application of the
EnVisionþ detection system (Dako Denmark A/S, #K4010),
with visualization using horseradish peroxidase and diami-
nobenzidine. Sections were counterstained with hematoxy-
lin and eosin, and dehydrated through alcohol and xylene
before mounting. For pharmacodynamic analyses, staining
intensity was scored semi-quantitatively in a blinded fashion
on a scale of 0–4.
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